All
Vitiligo Care Personalized for Each Patient: Part 1
Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.
Piperacillin/Tazobactam Shows Potential in Severe HS Treatment
Follow-up results showed that 6 out of 9 patients achieved HiSCR at 3 months, with 5 maintaining this response at 6 months.
FDA Approves Denileukin Diftitox for Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma
The approval is supported by positive phase 3 data for Lymphir in this indication.
Back to School, Back in the Spotlight
Young patients are heading back to school, and common skin issues like acne, eczema, warts, and pigmentation can affect their confidence, Shanna Miranti, MPAS, PA-C, writes.
Women With Skin of Color are Underrepresented in Studies of Treatments for Vulvar Lichen Sclerosus
Topical corticosteroids are the gold standard treatment for VLS, yet women with skin of color are not represented in studies.
Extended Guselkumab Dosing Proven Effective for Psoriasis
Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.
Study Achieves International Consensus for Methotrexate Dosing in Patients With Atopic Dermatitis
Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.
From OX40 Inhibition to Pediatric Pearls: Back-to-School Time for Physicians and Patients Alike
Our August issue covers common back-to-school skin conditions, psoriasis research, OX40 inhibition for atopic dermatitis, and pediatric dermatology meeting highlights.
Experts Form Consensus on AI's Role in Aesthetics
A group of international experts focused on the technology’s potential to standardize and enhance patient assessments.
Vitiligo Risk Alleles Vary Across Different Populations, According to Study
The findings highlight the need for diverse genetic studies to understand their broader impact on autoimmune diseases.
JAK Inhibition With Upadacitinib and Abrocitinib Shows Potential in Rosacea Treatment
Recent research evaluated 6 patients with rosacea treated with JAK1 inhibitors upadacitinib and abrocitinib.
Screening Questionnaire Developed for Type 2 Inflammation Diseases
The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.
Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis
Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.
Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment
A new method using 2 single-guide RNA/Cas9 tools to target 3 specific COL7A1 gene segments with harmful mutations successfully removed up to 95% of those segments.
Microneedling and CO2 Lasers Enhance Acne Treatment
A recent study revealed that CO2 fractional laser was significantly more effective than microneedling for acne treatment with ALA-PDT.
Relationship Between Vitiligo and Psoriasis May Be Due, In Part, to Immunity
Skin with vitiligo and psoriasis shows increased immune cell type, with a Mendelian analysis finding no causal link between the conditions.
Hand Dermatitis Relief: Cotton Gloves vs Sympatex Liners
Participants experienced improvements with both glove types, though cotton gloves were generally preferred for comfort and Sympatex for tactile sensitivity.
Journal Digest: August 5
This week’s collection of the latest dermatologic studies includes oral dutasteride for frontal fibrosing alopecia, effects of air pollutants for patients with acne, bimekizumab in patients with PsA without methotrexate, and itepekimab for adults with moderate to severe AD.
Topical vs Systemic Treatments: Rosacea Lesion Reduction Compared
A review of 43 studies found that systemic treatments generally provide greater reductions in rosacea ILs compared to topical therapies.
The Role of Vitamins and Nutrients in Rosacea Management
A recent study reviewed the current evidence on the impact of key vitamins and minerals on rosacea and provided clinical recommendations.
Climate and Atopic Dermatitis: 5 Recent Studies to Consider
A growing body of research is dedicated to understanding how various climatic elements impact AD.
Derm In The News: July 28-August 3
Keep up with the latest headlines in dermatology from the past week, including the FDA's warning to retailers to remove unapproved skin peel products, research into skin cells and their connection to Alzheimer's, and more.
The Weekly Roundup: July 29-August 2
In case you missed it, this week we had news about roflumilast cream 0.15%'s commercial availability for atopic dermatitis, Turn Therapeutics' new IGA and cytokine inhibition success with Hexagen, highlights from the 5CC World Congress, and more.
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Explore the disease progression of atopic dermatitis and strategies to make a difference in patients' lives.
Q&A: DaRT Guidelines for Nonmelanoma Skin Cancer Care
Jacob Scott, MD, president and chairman of DaRT, shares highlights of the guidelines and what he hopes clinicians can glean from them.
Diving Into Deuruxolitinib Data With Natasha Mesinkovska, MD, PhD
The investigator in the clinical development program for deuruxolitinib shared data, patient populations to consider, and more in a recent interview.
Exploring Safe Alternatives to BPO: Addressing Benzene Risks in Acne Treatments
While FDA action is awaited, dermatology clinicians can suggest BPO-free alternatives such as retinoids, salicylic acid, and more.
Q&A: Biologic Therapies in Pediatric Dermatology - Vaccines, Adverse Effects, and Personalized Care
Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.
Study Finds High Relapse Rate After Discontinuing PsO Biologics
Researchers suggested that early intervention with less than 2 years of disease duration was associated with a lower risk of relapse.
Documented Atopic Dermatitis Journeys and Patient Perspectives in Germany
The study focused on the use of Internet resources, number of medical consultations, and factors influencing treatment outcomes.